Skip to main contentSkip to navigation
Sirius Investors

PMXSF Stock: Pharmaxis Ltd Stock Price, Analysis & Insights

Get live PMXSF stock price $0.03, comprehensive Pharmaxis Ltd stock analysis, charts, news, and expert forecast. Real-time PMXSF stock data and investment insights.

0.03
0.00%Today
PMXSFPharmaxis Ltd • Other OTC • Healthcare
Market Cap
31.04M
Volume
150.00K
52W High
0.03
52W Low
0.03

Loading chart data...

Pharmaxis Ltd (PMXSF) Overview

Pharmaxis Ltd (PMXSF) is a publicly traded company in the Healthcare sector , specifically within the Drug Manufacturers - Specialty & Generic industry . As of the latest trading session, PMXSF trades at $0.03 with a market capitalization of 31.04M . Over the past 52 weeks, PMXSF has traded between $0.03 and $0.03 , with the current price positioned at approximately NaN% of this range . The sto...

Key Takeaways

  • Operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic)
  • Market cap: 31.04M
  • Current price: $0.03
  • 52-week range: $0.03 - $0.03
  • P/E ratio: 2.60

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Pharmaxis Ltd, an Australian biopharmaceutical company established in 1998 and headquartered in Frenchs Forest, specializes in the global research, development, and commercialization of therapeutic products for fibrotic and inflammatory diseases. Its...

Company Information

CEO
Gary Jonathan Phillips
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
27

Contact Information

Address
20 Rodborough Road
Country
AU

Investment Analysis & Business Insights

Healthcare
Drug Manufacturers - Specialty & Generic

Investment Highlights

Strong presence in the Healthcare sector with established market position

Valuation metrics suggest potential value opportunity (P/E: 2.6)

Lower volatility stock (Beta: 0.27) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Pharmaxis Ltd shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Pharmaxis Ltd
  • Investors should consider how Pharmaxis Ltd fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

31.04M

P/E Ratio (TTM)

2.60

Beta

0.27

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.